

1
2
3 **1 Title:**
4

5
6 2 The intra- and inter-observer reliability of a novel protocol for two-point discrimination in
7
8 3 individuals with chronic low back pain.
9

10 **4 Authors:**
11

12
13 5 Ehrenbrusthoff K^{1,2}, Ryan CG¹, Grüneberg C², Wolf U^{2,3}, Krenz D², Atkinson G¹, Martin DJ¹.
14

15 **6 Authors' Affiliations:**
16

17 7 ¹Health and Social Care Institute, Teesside University, Middlesbrough, UK, TS1 3BA
18

19 8 ²Hochschule fuer Gesundheit, Department of Applied Health Sciences, Gesundheitscampus 6-
20
21 8, 44801 Bochum, Germany
22

23
24 10 ³Hochschule Fulda, Department of Nursing and Health Sciences, Leipziger Strasse 123,
25
26 36037 Fulda, Germany
27
28

29 **12 Corresponding Author:**
30

31 13 Katja Ehrenbrusthoff, Department of Applied Health Sciences, Hochschule fuer Gesundheit
32
33 14 Bochum, Gesundheitscampus 6-8, 44801 Bochum, Germany, E-Mail:
34
35 15 katja.ehrenbrusthoff@hs-gesundheit.de
36
37
38

39 **16 Short Title:**
40

41
42 17 Low back 2-point discrimination reliability
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1 ABSTRACT**
4

5
6 2 Two-point discrimination is measured as an indicator of cortical reorganisation in
7
8 3 musculoskeletal medicine. Nevertheless, data are lacking for the reliability of this measure in
9
10 4 patients with non-specific chronic low back pain (NSCLBP). We aimed to quantify the intra-
11
12 5 and inter-observer reliability of a novel protocol for measuring two-point discrimination in
13
14 6 these patients. 35 participants (12 males, 23 females, mean age 52, SD 15years) with
15
16 7 NSCLBP were recruited. Three clinicians made 14 consecutive measurements of two-point
17
18 8 discrimination with callipers. One of these clinicians repeated the assessment protocol within
19
20 9 7 days. During each measurement, the calliper width was widened in 5-mm increments until
21
22 10 participants could consistently identify two points. Intra- and inter-observer agreement was
23
24 11 quantified using mean difference, within-subject SD and limits of agreement (LOA). After
25
26 12 using the first measurement for familiarisation, the mean of measurements 2 to 5 within an
27
28 13 assessment resulted in the optimum compromise between clinic time constraints and
29
30 14 acceptable intra-observer reliability; the within-subjects SD being 7.5 mm (LOA: 20.8 mm).
31
32 15 Inter-observer reliability was generally poorer; requiring the mean of measurements 2 to 9
33
34 16 within an assessment for a similar within-subjects SD of 8.6 mm (LOA: 23.7 mm). It was
35
36 17 estimated that these within-subjects SDs were small enough for a clinically-important change
37
38 18 to be detected with a feasible sample size in future studies. The intra-observer reliability of
39
40 19 our assessment protocol is acceptable for detecting a clinically relevant difference in two-
41
42 20 point discrimination for future research purposes. Nevertheless, individual patient
43
44 21 measurement variability is relatively high, especially between different clinicians.
45
46
47
48
49
50
51
52

53 **22 Key words:** Tactile acuity, reliability, low back pain, measurement
54
55
56
57
58
59
60

1 INTRODUCTION

2 It has been reported that the somatosensory cortex is disrupted in patients with chronic pain -
3 a phenomenon termed cortical reorganisation [1]. In patients with phantom limb pain and
4 complex regional pain syndrome, the degree of cortical reorganisation has been shown to
5 directly relate to their pain experience [2] and, as the pain intensity improves, the
6 somatosensory representation normalises [3]. While the mechanisms have not been fully
7 elucidated, normalisation of the somatosensory cortex is considered a viable target for the
8 treatment for pain patients [4]. Interventions attempting to normalise cortical reorganisation,
9 such as sensory discrimination training [5], have provided preliminary proof-of-concept for
10 such interventions.

11
12 Cortical reorganisation has been shown in patients with non-specific chronic low back pain
13 (NSCLBP) [6]. Furthermore, preliminary studies targeted at cortical reorganisation in
14 patients with NSCLBP have shown promising results [5, 7]. As interventions that target
15 cortical reorganisation for patients with NSCLBP become more common in clinical practice
16 and research, there is a need to ensure that cortical reorganisation can be measured reliably
17 and efficiently. The gold standard methods of measuring cortical reorganisation are functional
18 Magnetic Resonance Imaging (fMRI) and Electromagnetic Encephalography (EEG) [8].
19 These methods are very expensive, require sophisticated technology, skilled technicians and
20 can be time consuming. Therefore, there is a need to develop and appraise less expensive
21 assessment methods, which also have acceptable clinical utility.

22
23 Two-point discrimination (TPD) is a simple clinical test of tactile acuity, which measures the
24 minimum distance between two points on the skin that can be consciously detected [9].
25 Smaller distances indicate better acuity. Because TPD is correlated with cortical
26 reorganisation, it is commonly-used as a proxy measure of cortical reorganisation [10]. TPD

1
2
3 1 was initially developed to assess finger and hand tactile acuity [11]. More recently, studies
4
5
6 2 have used TPD to assess lower back tactile acuity as a proxy measure of lower back
7
8 3 somatosensory reorganisation [12, 13]. To date, only one research group has investigated the
9
10 4 reliability of lower back TPD and these researchers studied asymptomatic individuals [14].
11
12 5 Given that the test will be used clinically in patients with non-specific CLPB, there is a need
13
14 6 to directly assess the reliability of this technique in that population.
15
16
17 7

18
19
20 8 It has been highlighted that current TPD techniques involve a considerable amount of
21
22 9 subjectivity, where the clinician must make a judgement as to when sufficient consistency of
23
24 10 distance has been attained [15]. This can be clinically challenging, time consuming and can
25
26 11 introduce bias. There is a need to develop a TPD protocol, which reduces this source of
27
28 12 variability by minimising clinician judgment. The overarching aim of this study was to
29
30 13 develop and quantify the intra- and inter-observer reliability of a novel lower back TPD
31
32 14 assessment protocol, which minimises subjective clinical judgement, in patients with
33
34 15 NSCLBP. Specifically, the two objectives were to establish:
35
36
37
38
39 16

- 40
41 17 1. the minimum number of TPD measurements required within the assessment protocol
42
43 18 to maximise intra-observer reliability whilst minimising the time required to complete
44
45 19 the test;
46
47 20 2. the minimum number of TPD measurements required within the assessment protocol
48
49 21 to maximise inter-observer reliability whilst minimising the time required to complete
50
51 22 the test.
52
53 23
54
55 24
56
57 25
58
59 26
60

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

1 **METHODS**

2 **Study overview**

3 In this reliability study, 35 participants with NSCLBP underwent the same TPD test protocol
4 at three different time points to assess tactile acuity of the lower back. To assess intra-
5 observer reliability, assessor 1 measured TPD on day 1 and day 2. To assess inter-observer
6 reliability, a second assessor measured each participant on day 1 and this was compared to the
7 first assessor's measurement for day 1.

9 **Recruitment**

10 Patients were recruited consecutively from physiotherapy practices in Bochum, Germany
11 between June 2013 and December 2014. Participants had to meet the following inclusion
12 criteria: age \geq 18 years; NSCLBP with or without leg pain (for those with leg pain, the back
13 pain had to be dominant); duration of symptoms \geq 6 months; sufficient cognitive and German
14 language skills/ability to understand both oral and written instructions and to give informed
15 consent; intact skin on the lower back. Participants were excluded if they had signs and
16 symptoms indicating serious spinal pathologies (red flags). The study was approved by
17 Teesside University's School of Health and Social Care Research Governance and Ethics
18 Board and the Ethics committee of the German National Physiotherapists Society.

20 **Two-Point Discrimination Assessment Procedure**

21 The test procedure was developed from previous protocols for TPD threshold measurement
22 [16, 17]. Participants were positioned in a comfortable lying prone position on a treatment
23 bench with their back exposed. A pillow was positioned under the stomach to flatten the
24 lumbar spine. Feet were supported by a half roll for participant comfort. Using the
25 standardised palpation procedure according to Merz et al. [18], the tips of the transverse
26 processes of L5 were located and marked with a washable pen. The measurement tool was a

1
2
3 1 2-point discrimination caliper (Nexgen Medical Systems, Florida, USA) with a 1mm
4
5
6 2 precision. The calliper was applied, a sufficient amount of time to bring about the first
7
8 3 blanching of the skin and was then removed, no more than 1-2 seconds. The calliper was
9
10 4 placed horizontally to the spine and the transverse process of L5 was the center for the
11
12 5 calliper. Testing was carried out in an ascending (or widening) manner, starting with a
13
14 6 distance of 20mm between the two calipers and was increased in 5mm increments. This was
15
16 7 based upon preliminary rehearsals of process which found 1mm increments too time
17
18 8 consuming and distances between 0-20mm being constantly identified as one point. The time
19
20 9 between each increment was no more than a few seconds. The assessment was carried out at
21
22 10 one location of the lower back, either on the affected side or, with bilateral pain, on a prior
23
24 11 randomly identified side. Participants were advised to say 'one', when they felt one point and
25
26 12 'two' when they felt two points. Catch trials were also included approximately every 5
27
28 13 measurements by either using only one point or the widest possible distance. The distance at
29
30 14 which the participant first identified two points was noted. The callipers were then increased
31
32 15 by 5mm. If the participant again noted two points, this was considered to indicate consistency
33
34 16 of identification and the first distance of two-point identification was taken as the TPD result.
35
36 17 If, however, the participant did not identify the stimulus as two separate points after the 5mm
37
38 18 increment, the assessor continued to expand the distance until two consecutive correct ratings
39
40 19 were provided by the participant. This test procedure, operationally defined within this paper
41
42 20 as a measurement, was performed 14 times consecutively within each TPD assessment, with
43
44 21 the first test considered a practice. The decision to consider the first test as a practice was
45
46 22 based upon evidence of systematic effects, in that the first test was consistently poorer (a
47
48 23 wider TPD score) than subsequent measurements. After discarding the first test, we did not
49
50 24 find any clinically important upward or downward trend amongst the remaining
51
52 25 measurements.
53
54
55
56
57
58
59
60

26

1
2
3 **1 Order of testing**
4

5 2 One assessor (KE) carried out the TPD protocol with each participant on two separate days.
6

7 3 Day 1 and day 2 were never more than one week apart. Results between day 1 and day 2 for
8 4 assessor 1 were compared to assess intra-observer reliability. The mean of sessions were
9 5 consecutively calculated (i.e. mean of measurements 2 and 3, mean of measurements 2, 3 and
10 6 4 etc.) and compared either across day 1 and 2 for assessor 1. This was undertaken to identify
11 7 the number of individual TPD measurements needed within each TPD assessment to establish
12 8 a stable result within a clinically reasonable timeframe for a single assessor.
13
14

15
16
17
18
19
20
21
22 9

23
24 10 A second assessor (either DK or UW) carried out the TPD protocol on day 1 with each
25 11 participant immediately after assessor 1 had completed testing. Results between assessor 1
26 12 and 2 were compared to assess inter-observer reliability. Again the mean of sessions were
27 13 consecutively calculated (i.e. mean of tests 2 and 3, mean of tests 2, 3 and 4 etc.) and
28 14 compared across assessors. This was undertaken to identify the number of individual TPD
29 15 measurements needed within each TPD assessment to establish a stable result between raters
30 16 within a clinically reasonable timeframe.
31
32
33
34
35
36
37
38
39
40
41
42

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

17
18 All 3 assessors were comparably experienced physiotherapists with more than 15 years
19 working experience and postgraduate specialisation in Manual Therapy (IFOMPT degree).
20 KE had over 50 hours experience completing the TPD over the previous year period. UW and
21 DK received a 1-day training session prior to beginning the study, conducted by KE. All tests
22 were performed in treatment rooms in a laboratory-based setting in the Hochschule fuer
23 Gesundheit, Bochum, Germany.
24
25
26

1 **Clinical characteristics**

2 The following clinical measures were collected to provide a comprehensive clinical picture of
3 the participants and were in line with international recommendations regarding core sets of
4 outcome measures for back pain research [19, 20]: pain intensity (Brief Pain Inventory Short
5 Form); back related physical Function (Roland Morris Disability Questionnaire); anxiety and
6 depression (Hospital Anxiety and Depression Scale); health related quality of life (Euroqol
7 5D-3L). All questionnaires existed in a validated German version [21-23]. Demographics
8 including age, gender, height, weight, Body Mass Index (BMI), duration of symptoms and
9 working status were also documented.

10

11 **Statistical analysis**

12 For the adequate precision of sample estimates of error, Altman [24] advised the recruitment
13 of at least 40 participants for an agreement-type study like ours. Fifty-two people expressed
14 an interest in participating at the outset of the study. Seventeen people withdrew before the
15 first measurements were obtained or did not meet our inclusion/exclusion criteria resulting in
16 a final sample size of 35 participants (figure 1). Although this sample size is smaller than the
17 40 advised by Altman [24], we have reported 95% confidence intervals (95%CI) for the
18 reliability statistics. These 95%CIs are useful for ascertaining if the precision of estimate
19 affects the overall inferences that are made.

20

21 The greater the number of consecutive measurements averaged within a protocol period, the
22 closer the average of these measurements approaches the “true value” [25]. Nevertheless,
23 clinic time is obviously not exhaustive. Therefore, we examined intra- and inter-observer
24 reliability for a range of consecutive measurements made within the protocol period. The
25 mean (SD) systematic bias (and associated 95% confidence interval) between data collected
26 in repeated protocols and between different assessors was first quantified using a paired t-test.


1
2
3 1 Random error within and between assessors' measurements was quantified with the within-
4
5 2 subjects SD (standard error of measurement), coefficient of variation, limits of agreement, and
6
7 3 a random-error only (model 3.1) intra class correlation coefficients (ICC). Correlations which
8
9 4 collapse different components of bias, as well as random error between and within assessors
10
11 5 have been criticized in the literature for obfuscating separate sources of variability [25-27].
12
13 6 The within-subjects SD was then used as an input in statistical power calculations to estimate
14
15 7 whether the random measurement error was small enough to detect a clinically relevant
16
17 8 change in TPD with a feasible sample size [25, 28].
18
19
20
21
22 9

23 24 10 **RESULTS**

25 26 11 **Participant Characteristics**

27
28
29 12 Fifty-two people enquired about the study of which 35 met the inclusion criteria and
30
31 13 consented to participate; and all those who consented to participate completed the study
32
33 14 (figure 1). Of the 35, 20 were employed, 10 retired, 3 had retired early due to back pain, and 2
34
35 15 were on sick leave. The overall average for the intra-observer TPD data was 50.5mm (SD
36
37 16 19.2mm). The average levels of pain severity at time 1 and 2 were 3.6 and 3.5 respectively,
38
39 17 defined as mild-to-moderate severity [29]. The average back related physical function was
40
41 18 7.5, similarly defined as a mild-to-moderate disability [30]. For all participants, the area of
42
43 19 pain included the L5 level. The participant characteristics are detailed in table 1.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Figure 1:** Flow Chart of Participant Recruitment Process, Assessment for Eligibility, Testing
 2 and Data Analysis



3

1
2
3 **1 Intra-observer reliability**
4

5
6 **2** The mean difference between test days 1 and 2 in participants' levels of reported pain severity
7
8 **3** was 0.12 arbitrary units (95% CI: -0.25 to 0.48, $p=0.52$). The difference in pain interference
9
10 **4** scores between day 1 and 2 was 0.53 arbitrary units (95% CI: 0.27 to 0.80, $p<0.01$).
11
12

13 **5**
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Table 1:** Participant characteristics and clinical measures

	Mean (SD ^a)	Range
<u>Participant characteristics</u>		
Age (years)	52 (15)	22 - 79
Sex	12♂ 23♀	NR ^b
Height (m)	1.72 (0.1)	1.58 - 2.00
Weight (kg)	76 (17)	47 - 105
Body Mass Index (kg/m ²)	25 (5)	19 - 35
Symptom Duration (years)	11 (11)	0.5 - 40
<u>Clinical measures</u>		
BPI^c T1^d:		
Pain Severity	3.6 (2.0)	0.0 – 7.3
Pain Interference	2.6 (2.0)	0.0 – 8.4
BPI T2^e:		
Pain Severity	3.5 (1.9)	0.0 – 6.8
Pain Interference	2.1 (1.8)	0.0 – 6.9
RMDQ^f	7.5 (4.6)	1 – 18
HADS^g:		
Anxiety	5.2 (3.4)	0.0 – 15.0
Depression	4.5 (3.1)	0.0 – 14.0
EuroQol:		
Thermometer (%)	65 (21)	30 – 100
Index Value	0.81 (0.20)	0.18 – 1.00
Legend: ^a SD = Standard Deviation, ^b NR = Not Reported, ^c BPI= Brief Pain Inventory, ^d T1 = Session 1, ^e T2 = Session 2, ^f RMDQ = Roland Morris Disability Questionnaire, ^g HADS = Hospital Anxiety and Depression Scale		

2
3
4 The intra-observer reliability statistics for rater 1, and across all fourteen consecutive
5 measurements within the assessment, are shown in table 2. It was judged that taking the


1
2
3 1 average of consecutive measurements 2 to 5 resulted in the optimum trade-off between
4
5
6 2 measurement stability and the clinic time needed to complete testing. In clinical practice, the
7
8 3 shorter the time required to complete the better. The Bland and Altman plot for the individual
9
10 4 differences between days is shown in figure 2. The reliability appraisal was based on the
11
12 5 reasoning that for the mean of 2 to 5 measurements the systematic bias was less than 5mm
13
14
15 6 (the resolution of the measurement procedure) and the random error began to plateau with
16
17 7 further measurements resulting in minimal reductions in error in relation to the measurement
18
19
20 8 resolution. The 2-5 consecutive measurements took approximately 5 min to obtain with each
21
22 9 subsequent measure adding approximately 1 min for those participants with the poorest TPD
23
24 10 ability.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Table 2:** Intra-observer reliability
4

5 Number of tests	6 2	7 2 to 3	8 2 to 4	9 2 to 5	10 2 to 6	11 2 to 7	12 2 to 8	13 2 to 9	14 2 to 10	15 2 to 11	16 2 to 12	17 2 to 13	18 2 to 14
19 Mean session difference	20 3.4	21 3.6	22 5.5	23 4.0	24 3.9	25 3.4	26 2.7	27 1.9	28 1.3	29 1.3	30 0.6	31 0.4	32 0.3
33 SD ^a of session differences	34 17.7	35 12.8	36 11.5	37 10.6	38 11.4	39 11.3	40 11.0	41 10.8	42 10.8	43 10.4	44 9.8	45 10.5	46 10.1
47 Within-subjects SD (SEM ^b)	12.5	9.0	8.1	7.5	8.1	8.0	7.8	7.6	7.6	7.4	7.0	7.4	7.2
Coefficient of variation (%)	24.0	17.7	16.1	14.9	16.1	16.1	15.6	15.4	15.6	15.1	14.3	15.3	14.7
Limits of agreement	34.8	25.1	22.5	20.8	22.4	22.2	21.5	21.1	21.1	20.4	19.3	20.6	19.8
ICC ^c	0.65	0.80	0.81	0.85	0.82	0.82	0.83	0.83	0.83	0.84	0.85	0.83	0.85

2 **Legend:** Intra-observer reliability data for day 1 and 2 for rater 1 for 14 test repetitions with test 1 excluded as it was considered a practice test. The
3 values are based upon the cumulative test scores; ^aSD = Standard Deviation, ^bSEM = Standard error of measurement, ^c Intra class correlation
4 coefficient

1 **Figure 2:** The Limits of Agreement for intra-observer reliability



2
3 **Legend 2:** For intra-observer reliability, test-retest differences are plotted against the pooled
4 means for two sessions for measurement repetitions 2-5. Mean session differences (systematic
5 bias) are displayed by solid lines and limits of agreement by dashed lines.

6 **Inter-observer reliability**


7
8 The inter-observer reliability statistics between rater 1 and 2 across all fourteen measurements
9 are shown in table 3. The data for the two second raters were pooled as the inter-observer
10 reliability between rater 1 and both raters 2 and 3 were similar. Using the same reliability
11 criteria as above, it was judged that averaging the 2nd to 9th consecutive measurements
12 resulted in the optimum trade-off between measurement stability and the time needed to
13 complete testing. The Bland and Altman plot for these data is shown in figure 3. The
14 systematic bias was less than one unit of resolution (5mm) regardless of the number of
15 consecutive measurements.

1
2
3 **Table 3:** Inter-observer reliability
4

5 Number of tests	6 2	7 2 to 3	8 2 to 4	9 2 to 5	10 2 to 6	11 2 to 7	12 2 to 8	13 2 to 9	14 2 to 10	15 2 to 11	16 2 to 12	17 2 to 13	18 2 to 14
19 Mean session difference	20 3.8	21 2.2	22 2.0	23 1.3	24 1.4	25 0.9	26 0.6	27 -0.1	28 -0.8	29 -1.0	30 -1.8	31 -2.1	32 -2.2
33 SD of session differences	34 22.4	35 18.8	36 16.0	37 15.4	38 14.6	39 13.3	40 13.2	41 12.8	42 13.1	43 13.2	44 13.3	45 13.0	46 13.0
47 Within-subjects SD ^a (SEM ^b)	15.8	12.8	10.9	10.5	10.3	9.3	9.0	8.6	8.7	8.7	8.7	8.6	8.3
Coefficient of variation (%)	29.9	23.9	20.4	19.5	19.5	17.8	17.3	16.7	17.1	17.2	17.3	17.0	16.5
Limits of agreement	43.8	35.4	30.3	29.0	28.6	25.9	24.9	23.7	24.0	24.2	24.2	23.7	23.0
ICC ^c	0.30	0.53	0.66	0.70	0.70	0.74	0.75	0.76	0.75	0.74	0.74	0.75	0.77

2 **Legend:** Inter-observer reliability data for observer 1 and observer 2 for 14 consecutive measurements with test 1 excluded as it was considered a
3 practice test. The values are based upon the cumulative measurement scores. The values for rater 2 are the combined values for DK who measured
4 22 of the participants and UW who measured 13 of the participants. Data for both 2nd raters were sufficiently similar with respect to reliability with
5 rater 1 to allow pooling of the data; ^aSD = Standard Deviation, ^bSEM = Standard error of measurement, ^cICC= Intra class correlation coefficient
6
7
8

1 **Figure 3:** The limits of agreement for inter-observer reliability



3 **Legend 3:** For inter-observer reliability, the differences from rater 1 and the pooled
4 differences for rater 2 are plotted against the pooled means for measurement repetition 2-9.
5 Mean session differences (systematic bias) are displayed by solid lines and limits of
6 agreement by dashed lines.

8 Discussion

9 The overarching aim of this study was to develop and quantify the intra- and inter-observer
10 reliability of a novel lower back TPD assessment protocol, which minimises subjective
11 clinical judgement, in patients with NSCLBP. The study had two objectives - to establish: 1.
12 the minimum number of TPD measurements required within the assessment protocol to
13 maximise intra-observer reliability whilst minimising the time required to complete the test;
14 and 2. the minimum number of TPD measurements required within the assessment protocol to
15 maximise inter-observer reliability whilst minimising the time required to complete the test?

16
17 Five measurements (with the first used as a practice trial only and not used to calculate the
18 mean) was identified as the minimum number of TPD measurements required within the TPD

1
2
3 1 assessment protocol to maximise intra-observer reliability whilst minimising the time required
4
5 2 to complete the test (approximately 5 minutes). Nine measurements (with the first used as a
6
7
8 3 practice trial only and not used to calculate the mean) was identified as the minimum number
9
10 4 of TPD measurements required within the TPD assessment protocol to maximise inter-
11
12 5 observer reliability whilst minimising the time required to complete the test (approximately 9
13
14 6 minutes).

15
16
17 7
18
19 8 Only one previous study has investigated the intra- and inter-observer reliability of the TPD
20
21 9 for the lower back [14]. In this study, 28 clinicians assessed the TPD of the lower back in 28
22
23 10 healthy young adults. The mean TPD reported was 55.5mm (SD 12.7mm) with an intra-
24
25 11 observer ICC of 0.81 and inter-observer ICC 0.86; and an intra-observer limits of agreement
26
27 12 of (mean difference [lower limit to upper limit]) 0.6mm [-14.1 to 15.4] and an inter-observer
28
29 13 reliability limits of agreement of (1.9mm [-19.0 to 22.8]). In our study, the mean TPD
30
31 14 reported was 50.5mm (SD 19.2mm) with an intra-observer ICC of 0.85 and inter-observer
32
33 15 ICC 0.76; and an intra-observer limits of agreement of (mean difference [lower limit to upper
34
35 16 limit]) 4.0mm [-16.8 to 24.8] and inter-observer reliability limits of agreement of (-0.1mm [-
36
37 17 23.8 to 23.7]). Broadly, the level of systematic error and the ICCs were similar between
38
39 18 studies though our study had slightly wider limits of agreement. This is likely due to the
40
41 19 inherent greater variability that would be expected in participants with low back pain
42
43 20 compared with healthy participants.
44
45
46
47
48
49

50 21
51
52 22 In a meta-analysis, Catley et al [31] indicated that a minimal clinically important difference in
53
54 23 TPD between NSCLBP patients and healthy controls is 11.7 mm (26%). Using these values as
55
56 24 a basis for a power estimation and our intra-observer reliability within-subjects SD of 7.5 mm,
57
58 25 it can be estimated that 11 participants would be required for a future single arm pre-post
59
60 26 study (two-tailed $P < 0.05$, statistical power = 90%). We also estimate that 44 participants (22

1
2
3 1 in each study arm) would be required for a future two-arm randomised controlled trial, which
4
5 2 is a reasonably achievable sample size within the musculoskeletal rehabilitation research
6
7
8 3 context. Hence, our TPD assessment protocol can be seen as possessing acceptable intra-
9
10 4 observer reliability as a measure of tactile acuity for research purposes.
11
12
13 5

14
15 6 Whether this measure is sufficiently reliable to detect change on an individual patient basis
16
17 7 within a clinical setting is less clear. The SEM (or typical error) identified in our study was
18
19 8 7.5mm, which is below the MCID of 11.7mm in the literature. Nevertheless, with 95% limits
20
21 9 of agreement of ± 20.8 mm, it can be estimated that an individual back pain patient could
22
23 10 change, in a worst scenario, by as much as 20.8 mm due to normal variation with this
24
25 11 measure. This questions its usefulness in clinical practice, based on the assumption that 11.7
26
27 12 mm is a clinically relevant change. This minimum clinically important difference (MCID)
28
29 13 was estimated from a systematic review comparing individuals with back pain to healthy
30
31 14 controls [15] rather than from a formal estimation of what is a clinically relevant
32
33 15 improvement in patients with back pain. Further work needs to be undertaken to establish the
34
35 16 MCID for back pain patients before firm conclusions can be made about the reliability of our
36
37 17 TPD assessment protocol. Reliability decisions are inherently contingent on the magnitude of
38
39 18 the MCID [25].
40
41
42
43
44
45
46
47

48 20 It has previously been identified that the need for assessor judgement to quantify the exact
49
50 21 TPD in previous protocols has introduced considerable capacity for bias [14]. This study is
51
52 22 the first to present a detailed protocol which eliminates that judgement. While it is not
53
54 23 possible from our data to examine the effect this judgement elimination has had on reliability,
55
56 24 it is reasonable to suggest that it will help to reduce bias. It would be interesting to compare
57
58 25 our TPD protocol with previous protocols that did require assessor judgement to investigate
59
60 26 what effect, if any, assessor judgment has on TPD reliability in the lower back region.

1 **Clinical Implications**

2 The implications of the higher inter-rater reliability compared with the intra-rater reliability
3 are that fewer measurements are needed when 1 clinician is treating and monitoring the same
4 patient, than when test results from more than one clinician are being used. Our findings
5 indicate that the mean of 5 TPD measurements (with the first considered a practice and not
6 used to calculate the mean) provided the optimum balance of intra-observer reliability aspects
7 and practical duration of testing with one clinician. For two clinicians, we identified 9
8 measurements (with the first considered a practice and not used to calculate the mean) as the
9 optimum balance of inter-observer reliability aspects and duration of testing. These figures
10 should be interpreted cautiously in light of the limitations outlined below.

11

12 **Strengths and limitations**

13 One limitation in all measurement studies is sample size and, although 52 participants were
14 contacted initially to take part, our final sample size for analysis was slightly lower than
15 established recommendations of 40 participants [24]. This recommendation was based on the
16 adequate precision of estimate of a sample SD. Precision of statistical estimates is indicated
17 by the 95% CIs. It can be seen in table 4 that these are sufficiently narrow not to alter our
18 conclusions that the assessment protocol is useful for research but unclear in terms of
19 reliability of clinical decisions made on individual patients. Our participant sample size is also
20 somewhat larger than those in other related studies [14, 32, 33].

1 **Table 4:** Intra- and Inter-observer reliability for the recommended number of test repetitions

Number of tests	<u>Intra-observer</u>		<u>Inter-observer</u>	
	2 to 5	2 to 5	2 to 5	2 to 9
Mean session difference (95% CI)	4.0 (0.49-7.51)	1.3 (-3.84-6.34)	-0.1(-4.07-3.96)	
SD ^a of session differences	10.6 (8.6-13.9)	15.4 (12.5-20.2)	12.8 (10.4-16.8)	
Within-subjects SD (SEM ^b)	7.5 (6.1-9.8)	10.5 (8.8-14.2)	8.6 (7.4-11.9)	
Coefficient of variation (%)	14.9 (12.1-19.4)	19.5 (16.4-26.5)	16.7 (14.4-23.2)	
Limits of agreement	20.8 (16.9-27.2)	29.0 (24.5-39.6)	23.7 (20.4-32.9)	
ICC ^c (95% CI ^d)	0.85 (0.72-0.92)	0.70 (0.48-0.84)	0.76 (0.57-0.87)	

2 **Legend:** Intra-observer reliability data for day 1 and 2 for rater 1 for 5 measurements with
 3 measurement 1 excluded as it was considered a practice measurement. Inter-observer
 4 reliability data for rater 1 and rater 2 (pooled) for 5 and 9 measurements with measurement 1
 5 excluded respectively. The values are based upon the cumulative test scores. The values for
 6 the 95% Confidence Intervals were calculated according to the recommended method by Zar
 7 [34]; ^aSD = Standard Deviation, ^bSEM = Standard error of measurement, ^cICC= Intra class
 8 correlation coefficient, ^dCI = Confidence Interval

9
 10 One practical limitation of our assessment protocol is that it is carried out in prone lying.
 11 While this in line with other protocols, there is the possibility that for some people with back
 12 pain this may be uncomfortable, which could affect the practicality of testing. Future studies
 13 could be carried out to investigate the measurement properties of this assessment protocol in
 14 sitting.

15 Because of our limited number of assessors and the fact that they were experienced in the use
 16 of the protocol, the findings of the present study should not be directly generalized to any
 17 other assessor using the same protocol. That will require further work with a larger number of

1 assessors. Also, all of our assessors were experienced and so we cannot comment on the
2 influence of experience. That said, a previous study has suggested that this factor is of limited
3 importance [14].

4 In addition, a further limitation could constitute the use of catch trials. We used catch trials in
5 keeping with previous protocols [12, 17, 35] in order to account for potential effects of
6 participants guessing. However, patients may be more likely to report the application of a
7 stimuli after a catch trial as ‘two points’ simply because it feels different (e.g. *duller or*
8 *coarser*) from “one point” but not because of any perceived difference in spatial acuity [36].
9 Thus the use of catch trials could artificially lower a patient’s TPD. This may explain why the
10 TPD measurements reported in our study are lower than those reported by others [15].
11 Further work could compare the current assessment protocol to another not using catch trials
12 or employing them differently to weigh up the effects of these catch trials.

13 The primary strength of this study was the comprehensive range of statistical estimates used
14 for quantifying the systematic and random changes that can occur in a reliability study [25].
15 We concentrated on absolute indicators of reliability such as the within-subjects SD in order
16 to arrive at our conclusions, especially in terms of extrapolating how the degree of reliability
17 might impact on future research. Standard procedures for quantifying systematic bias tend to
18 include the reporting of ICCs. However, in samples with large heterogeneity, a high ICC
19 might obfuscate substantial and clinically relevant random error [37]. It also does not make
20 sense to use a type of ICC which combines systematic and random errors into a single value,
21 because the solutions to reducing systematic and random errors can be very different [26].

22
23 Another strength of the present study constituted the TPD focus on the population of patients
24 with NSCLBP. As mentioned earlier, the TPD reliability data in a young and healthy
25 population displayed a large variability [14]. With the expectation of an even greater

1
2
3 1 heterogeneity in a population with back pain, here was a need to specifically look at reliability
4
5 2 of the test in this population.
6
7
8 3

9
10 4 A final strength of this study was that the participants were clinically stable between
11
12 5 assessment times 1 and 2. While there was a statistically significant improvement in pain
13
14 6 interference between time 1 and 2 this difference was lower than 1 unit on the BPI, which is
15
16 7 not considered to be clinically relevant. [38]. Such stability between measures is an important
17
18 8 methodological issue in reliability studies [39].
19
20
21
22 9

23 24 10 **Conclusion**

25
26
27 11 This study presented data on the development and reliability assessment of a novel TPD
28
29 12 assessment protocol for the lower back. The protocol attempted to overcome previously noted
30
31 13 limitations of TPD measurement protocols that require assessor judgement. This study found
32
33 14 that five measurements (with the first used as a practice trial only and not used to calculate the
34
35 15 average) was the minimum number of TPD measurements required within the assessment
36
37 16 TPD protocol to maximise intra-observer reliability whilst minimising the time required to
38
39 17 complete the assessment. Additionally, nine measurements (with the first used as a practice
40
41 18 trial only and not used to calculate the average) should be used as the minimum number of
42
43 19 TPD measurements within the assessment protocol to maximise inter-observer reliability
44
45 20 whilst minimising the time required to complete the assessment. The protocol described
46
47 21 demonstrates a level of intra-observer reliability sufficient for research purposes. However, it
48
49 22 is unclear, as yet, whether the level of reliability is sufficient for individual patient
50
51 23 measurements in clinical practice.
52
53
54
55
56
57
58
59
60

25 24 **Conflict of Interest**

26 The authors have no conflicts of interest to declare.

References

- 1 Moseley GL. Pain, brain imaging and physiotherapy—Opportunity is knocking. *Manual therapy* 2008;13(6):475-7.
- 2 Flor H. Cortical reorganisation and chronic pain: implications for rehabilitation. *Journal of Rehabilitation Medicine* 2003;35(0):66-72.
- 3 Flor H, Denke C, Schaefer M, Gruesser S. Effect of sensory discrimination training on cortical reorganisation and phantom limb pain. *The Lancet* 2001;357(9270):1763-4.
- 4 Moseley L, Flor H. Targeting cortical representations in the treatment of chronic pain: a review. *Neurorehabil Neural Repair* 2012;26(Suppl 6):646 - 52.
- 5 Wand BM, O'Connell NE, Di Pietro F, Bulsara M. Managing Chronic Nonspecific Low Back Pain With a Sensorimotor Retraining Approach: An Exploratory Multiple-Baseline Study of 3 Participants. *Physical Therapy* 2011.
- 6 Flor H, Braun C, Elbert T, Birbaumer N. Extensive reorganization of primary somatosensory cortex in chronic back pain patients. *Neuroscience Letters* 1997;224(1):5-8.
- 7 Wand BM, Abbaszadeh S, Smith AJ, Catley MJ, Moseley GL. Acupuncture applied as a sensory discrimination training tool decreases movement-related pain in patients with chronic low back pain more than acupuncture alone: a randomised cross-over experiment. *British Journal of Sports Medicine* 2013;47(17):1085-9.
- 8 Diers M, Koeppe C, Diesch E, et al. Central processing of acute muscle pain in chronic low back pain patients: an EEG mapping study. *Journal of Clinical Neurophysiology* 2007;24(1):76-83.
- 9 Nolan MF. Quantitative measure of cutaneous sensation two-point discrimination values for the face and trunk. *Physical Therapy* 1985;65(2):181-5.
- 10 Moseley GL, Flor H. Targeting Cortical Representations in the Treatment of Chronic Pain A Review. *Neurorehabilitation and neural repair* 2012;26(6):646-52.
- 11 Moberg E. Two Point Discrimination Test. *Scandinavian Journal of Hand Surgical Rehabilitation* 1990;22:8.
- 12 Moseley GL. I can't find it! Distorted body image and tactile dysfunction in patients with chronic back pain. *Pain* 2008;140:239-43.
- 13 Loumajoki H, Moseley G. Tactile acuity and lumbopelvic motor control in patients with back pain and healthy controls. *Br J Sports Med* 2011;45:437 - 40.
- 14 Catley MJ, Tabor A, Wand BM, Moseley GL. Assessing tactile acuity in rheumatology and musculoskeletal medicine—how reliable are two-point discrimination tests at the neck, hand, back and foot? *Rheumatology* 2013.
- 15 Catley MJ, O'Connell NE, Berryman C, Ayhan FF, Moseley GL. Is tactile acuity altered in people with chronic pain? A systematic review and meta-analysis. *The Journal of Pain* 2014;15(10):985-1000.
- 16 Dinse HR, Kleibel N, Kalisch T, Ragert P, Wilimzig C, Tegenthoff M. Tactile coactivation resets age-related decline of human tactile discrimination. *Annals of Neurology* 2006;60(1):88-94.
- 17 Wand B, Di Pietro F, George P, O'Connell NE. Tactile thresholds are preserved yet complex sensory function is impaired over the lumbar spine of chronic non-specific low back pain patients. A preliminary investigation. *Physiotherapy* 2010;96:317-23.
- 18 Merz O, Wolf U, Robert M, Gesing V, Rominger M. Validity of palpation techniques for the identification of the spinous process L5. *Manual therapy* 2013.
- 19 Deyo RA, Battie M, Beurskens AJHM, et al. Outcome Measures for Low Back Pain Research: A Proposal for Standardized Use. *Spine* 1998;23(18):2003-13.
- 20 Bombardier C. Outcome Assessments in the Evaluation of Treatment of Spinal Disorders: Summary and General Recommendations. *Spine* 2000;25(24):3100-3.

- 1
2
3 21 Radbruch L, Loick G, Kiencke P, et al. Validation of the German Version of the Brief
4 Pain Inventory. *Journal of pain and symptom management* 1999;18(3):180-7.
5
6 22 Wiesinger GF, Nuhr M, Quittan M, Ebenbichler G, Woelfl G, Fialka-Moser V. Cross-
7 Cultural Adaptation of the Roland-Morris Questionnaire for German-Speaking
8 Patients With Low Back Pain. *Spine* 1999;24(11).
9
10 23 Oesch P, Hilfiker R, Keller S, et al. *Assessments in der Rehabilitation Band 2:*
11 *Bewegungsapparat*. Bern: Verlag Hans Huber; 2011.
12
13 24 Altman DG. *Practical statistics for medical research*. New York;London;: Chapman
14 and Hall; 1991.
15
16 25 Atkinson G, Nevill AM. Statistical methods for assessing measurement error
17 (reliability) in variables relevant to sports medicine. *Sports medicine* 1998;26(4):217-
18 38.
19
20 26 Atkinson G, Nevill A. Comment on the use of concordance correlation to assess the
21 agreement between two variables. *JSTOR*; 1997.
22
23 27 Weir JP. Quantifying test-retest reliability using the intraclass correlation coefficient
24 and the SEM. *The Journal of Strength & Conditioning Research* 2005;19(1):231-40.
25
26 28 Batterham AM, Atkinson G. How big does my sample need to be? A primer on the
27 murky world of sample size estimation. *Physical Therapy in Sport*;6(3):153-63.
28
29 29 Palos GR, Mendoza TR, Mobley GM, Cantor SB, Cleeland CS. Asking the
30 Community About Cutpoints Used to Describe Mild, Moderate, and Severe Pain. *The*
31 *Journal of Pain* 2006;7(1):49-56.
32
33 30 Roland M, Fairbank J. The Roland Morris Disability Questionnaire and the Oswestry
34 Disability Questionnaire. *Spine* 2000;25(24).
35
36 31 Catley MJ, Tabor A, Miegel RG, Wand BM, Spence C, Moseley GL. Show me the
37 skin! Does seeing the back enhance tactile acuity at the back? *Manual Therapy*
38 2014;19(5):461-6.
39
40 32 Luomajoki H, Lean C, Di Pietro F, Ariaksinen O. Reliability of movement control
41 tests in the lumbar spine. *BMC Musculoskeletal Disorders* 2007;8(90).
42
43 33 Tidstrand J, Horneij E. Inter-rater reliability of three standardized functional tests in
44 patients with low back pain. *BMC Musculoskeletal Disorders* 2009;10(1):58.
45
46 34 Zar J. *Biostatistical analysis* (p. 663). New Jersey: Prentice Hall 1999.
47
48 35 Peters ML, Schmidt AJ. A comparison of two-point discrimination threshold of
49 tactual, non-painful stimuli between chronic low back pain patients and controls. *Pain*
50 1991;44(1):57-60.
51
52 36 Johnson KO, Van Boven RW, Hsiao SS. The perception of two points is not the
53 spatial resolution threshold. *Touch, temperature, and pain in health and disease:*
54 *Mechanisms and assessments* 1994:389-404.
55
56 37 Bland JM, Altman DG. A note on the use of the intraclass correlation coefficient in the
57 evaluation of agreement between two methods of measurement. *Computers in biology*
58 *and medicine* 1990;20(5):337-40.
59
60 38 Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the Clinical Importance of
Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations.
The Journal of Pain 2008;9(2):105-21.
39
40 39 Mokkink LB, Terwee CB, Patrick DL, et al. *The COSMIN checklist manual*.
Amsterdam: VU University Medical Centre 2009.